

FIGURES 1A-D
002007-0022960








FIGURE 1E



FIGURES 2A-D






PHOTO AT



Figures 3A&B

Log₁₀ Viral Load (Roche Amplicor) \times Log₁₀ Viral Load Δ CD4T cells/ml



D

IU hCG/week \times 1,000


Time (weeks)	IU hCG/week \times 1,000
-2.8	~0.5
-1.8	~0.5
-0.47	~0.5
0	~0.5
0.5	~0.5
0.93	~0.5
1.87	~0.5
2.9	~0.5
3.4	~0.5
3.83	~0.5
4.07	~0.5
4.3	~0.5
4.77	~0.5

3tc,
ddi


Figures 3c and D

Duration of hCG₁ Treatment (max)


Time (weeks)	Duration of hCG ₁ Treatment (max)
-2.8	~0.5
-1.8	~0.5
-0.47	~0.5
0	~0.5
0.5	~0.5
0.93	~0.5
1.87	~0.5
2.9	~0.5
3.4	~0.5
3.83	~0.5
4.07	~0.5
4.3	~0.5
4.77	~0.5



Figures 3 E & F




Figures 3G and H



002001" 2374360

FIGURES 4A-D




p24 ng/ml




002007 2372960

FIGURES 5A-C

Effect of preparation of hCG on HIV-LTR activity



8769-024



09677152 100200

09677152-100200




FIGURE 6B-H

000007" 25T 22960

- ☐ None
- ☒ ahCG
- ☒ hCGapI
- ☒ Nb hCG
- ☐ CR127
- ☒ b109-119
- ☒ b45-57
- ☒ b45-57c
- ☒ bmix45+109


1000

100


10

Number of colonies


A



B



C




FIGURES 7A-C

FIGURE 8

AGACAAGGCA GGGGACGCAC CAAGG	ATG GAG ATG TTC CAG GGG CTG CTG CTG	52
	Met Glu Met Phe Gln Gly Leu Leu Leu	
	-20	
TTG CTG CTG CTG AGC ATG GGC GGG ACA TGG GCA TCC AAG GAG CCG CTT		100
Leu Leu Leu Leu Ser Met Gly Gly Thr Trp Ala Ser Lys Glu Pro Leu		
	-10	
	-5	
CGG CCA CGG TGC CGC CCC ATC AAT GCC ACC CTG GCT GTG GAG AAG GAG		148
Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu		
	10	
	15	
GGC TGC CCC GTG TGC ATC ACC GTC AAC ACC ACC ATC TGT GCC GGC TAC		196
Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr		
	25	
	30	
TGC CCC ACC ATG ACC CGC GTG CTG CAG GGG GTC CTG CCG GCC CTG CCT		244
Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro		
	40	
	45	
CAG GTG GTG TGC AAC TAC CGC GAT GTG CGC TTC GAG TCC ATC CGG CTC		292
Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu		
	55	
	60	
CCT GGC TGC CCG CGC GGC GTG AAC CCC GTG GTC TCC TAC GCC GTG GCT		340
Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala		
	70	
	75	
CTC ACC TGT CAA TGT GCA CTC TGC CGC CGC AGC ACC ACT GAC TGC GGC		388
Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly		
	90	
	95	
GGT CCC AAG GAC CAC CCC TTG ACC TGT GAT GAC CCC CGC TTC CAG GAC		436
Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp		
	105	
	110	
TCC TCT TCC TCA AAG GCC CCT CCC CCC AGC CTT CCA AGC CCA TCC CGA		484
Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg		
	120	
	125	
CTC CCG GGG CCC TCG GAC ACC CCG ATC CTC CCA CAA TAAAGGCTTC		530
Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln		
	135	
	140	
	145	
TCAATCCGC		539

096775E-100200

Figures 10A-F



% Inhibition of KS Colony Growth






Figure 11

09677152 100200

Figure 13



%Increase of Hematopoiesis



Figures 12 A - C

% Survival of Tg26 mice




Figure 14

09677152 . 100200

1970-1971	100
1972-1973	100
1974-1975	100
1976-1977	100
1978-1979	100
1980-1981	100
1982-1983	100
1984-1985	100
1986-1987	100
1988-1989	100
1990-1991	100
1992-1993	100
1994-1995	100
1996-1997	100
1998-1999	100
2000-2001	100
2002-2003	100
2004-2005	100
2006-2007	100
2008-2009	100
2010-2011	100
2012-2013	100
2014-2015	100
2016-2017	100
2018-2019	100
2020-2021	100
2022-2023	100
2024-2025	100
2026-2027	100
2028-2029	100
2030-2031	100
2032-2033	100
2034-2035	100
2036-2037	100
2038-2039	100
2040-2041	100
2042-2043	100
2044-2045	100
2046-2047	100
2048-2049	100
2050-2051	100
2052-2053	100
2054-2055	100
2056-2057	100
2058-2059	100
2060-2061	100
2062-2063	100
2064-2065	100
2066-2067	100
2068-2069	100
2070-2071	100
2072-2073	100
2074-2075	100
2076-2077	100
2078-2079	100
2080-2081	100
2082-2083	100
2084-2085	100
2086-2087	100
2088-2089	100
2090-2091	100
2092-2093	100
2094-2095	100
2096-2097	100
2098-2099	100
2100-2101	100
2102-2103	100
2104-2105	100
2106-2107	100
2108-2109	100
2110-2111	100
2112-2113	100
2114-2115	100
2116-2117	100
2118-2119	100
2120-2121	100
2122-2123	100
2124-2125	100
2126-2127	100
2128-2129	100
2130-2131	100
2132-2133	100
2134-2135	100
2136-2137	100
2138-2139	100
2140-2141	100
2142-2143	100
2144-2145	100
2146-2147	100
2148-2149	100
2150-2151	100
2152-2153	100
2154-2155	100
2156-2157	100
2158-2159	100
2160-2161	100
2162-2163	100
2164-2165	100
2166-2167	100
2168-2169	100
2170-2171	100
2172-2173	100
2174-2175	100
2176-2177	100
2178-2179	100
2180-2181	100
2182-2183	100
2184-2185	100
2186-2187	100
2188-2189	100
2190-2191	100
2192-2193	100
2194-2195	100
2196-2197	100
2198-2199	100
2200-2201	100
2202-2203	100
2204-2205	100
2206-2207	100
2208-2209	100
2210-2211	100
2212-2213	100
2214-2215	100
2216-2217	100
2218-2219	100
2220-2221	100
2222-2223	100
2224-2225	100
2226-2227	100
2228-2229	100
2230-2231	100
2232-2233	100
2234-2235	100
2236-2237	100
2238-2239	100
2240-2241	100
2242-2243	100
2244-2245	100
2246-2247	100
2248-2249	100
2250-2251	100
2252-2253	100
2254-2255	100
2256-2257	100
2258-2259	100
2260-2261	100
2262-2263	100
2264-2265	100
2266-2267	100
2268-2269	100
2270-2271	100
2272-2	

A




Figure 15B

CD4 Change After HAF





Figure 15C

Viral Load Versus HAF Dose



Figures 16 A and B






FIGURE 17A

Counts



Method: PRO60K_L
Mode: Linear

Accelerating Voltage: 25000

Grid Voltage: 88.000 %

Guide Wire Voltage: 0.200 %

Delay: 300 ON

Laser: 2600

Scans Averaged: 52

Pressure: 4.64e-07

Low Mass Gate: 500.0

Collected: 1/28/97 8:06 PM


Mirror Ratio: 1.060

PSD Mirror Ratio:

Timed Ion Selector: 15.5 OFF

Negative Ions: OFF

FIGURE 17B



Method: PRO60K_L

Mode: Linear

Accelerating Voltage: 25000

Grid Voltage: 88.000 %

Guide Wire Voltage: 0.200 %

Delay: 300 ON

Laser : 2700

Scans Averaged: 90

Pressure: 3.40e-07

Low Mass Gate: 500.0

Collected: 1/28/97 8:11 PM


Mirror Ratio: 1.060

PSD Mirror Ratio:

Timed Ion Selector: 15.5 OFF

Negative Ions: OFF

FIGURE 17C



Method: PRO60K_L
Mode: Linear


Accelerating Voltage: 25000
Grid Voltage: 88.000 %
Guide Wire Voltage: 0.200 %

Delay: 300 ON
Laser : 2408
Scans Averaged: 125
Pressure: 3.12e-07
Low Mass Gate: 500.0

Mirror Ratio: 1.060
PSD Mirror Ratio:
Timed Ion Selector: 15.5 OFF
Negative Ions: OFF

FIGURE 17D

Counts



Method: PRO60K_L

Mode: Linear

Accelerating Voltage: 25000

Grid Voltage: 88.000 %

Guide Wire Voltage: 0.200 %

Delay: 300 ON

Laser : 2700

Scans Averaged: 57

Pressure: 3.02e-07

Low Mass Gate: 500.0

Collected: 1/28/97 8:14 PM

Mirror Ratio: 1.060


PSD Mirror Ratio:

Timed Ion Selector: 15.5 OFF

Negative Ions: OFF

09677152.100200

FIGURE 17E



Method: PRO60K_L

Mode: Linear

Accelerating Voltage: 25000

Grid Voltage: 88.000 %

Guide Wire Voltage: 0.200 %

Delay: 300 ON

Laser: 2700

Scans Averaged: 45

Pressure: 2.87e-07

Low Mass Gate: 500.0

Mirror Ratio: 1.060

PSD Mirror Ratio:

Timed Ion Selector: 15.5 OFF


Negative Ions: OFF

A	B	C	D
1	2	3	4
5	6	7	8
9	10	11	12


FIGURES 18 A-H

FIGURE 19

Prostate (colonyogenic assay)



Systemic Effects of 125 I-hCG Preparation or 125 I-hCG Peptide Induces Apoptosis in Prostate Tumors of Nude Mice



FIGURES 20A-C

09674152 100200

002007 2972650




FIGURE 21

002007 23724350

Clonogenic Assay lung 177




FIGURE 22A

002007 237/350




FIGURE 22B

002007" 2374350




FIGURE 22C

lung cancer

Apr.

Lung 177/May

B

C...

A

W

U

125.00m

09677452 100300

FIGURES 23A-F

FIGURES 24A-I

